Moderna, Inc. (BMV:MRNA)

Market Cap	188.08B
Revenue (ttm)	64.93B
Net Income (ttm)	-68.61B
Shares Out	n/a
EPS (ttm)	-178.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,926
Average Volume	5,130
Open	487.00
Previous Close	455.90
Day's Range	482.50 - 495.00
52-Week Range	454.50 - 2,820.00
Beta	n/a
RSI	42.14
Earnings Date	May 1, 2025

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 5,800
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: MRNA

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD